Moreover, when glucagon secretion is inadequate, as in the setting of hypoglycemia in type 1 diabetes, somatostatin receptor antagonism improves counterregulatory responses to improve blood glucose stability.11–13 These varied observations likely stem from cell-specific effects of SST action, as well as spatially regulated somatostatin signaling within subcellular compartments. This evidence concerns the gene SST and type 1 diabetes mellitus.